A qualitative substudy of 10 youth with type 1 diabetes and high HbA1c describing their lived experience of starting advanced hybrid closed-loop therapy. PICO summary and expert commentary.
Browsing: Type 1 Diabetes
A TrialNet post hoc analysis in 40 high-risk relatives found oral insulin favourably shifted a combined glucose and C-peptide surrogate (p=0.037), not a proven delay in diabetes onset. PICO summary and expert commentary.
A manufacturer-funded cost-effectiveness model found the MiniMed 780G closed-loop system cost-effective versus injections with isCGM in US type 1 diabetes at $100,000 per QALY (ICER $68,402 over 4 years, $38,842 lifetime). PICO summary and expert commentary.
A double-blind RCT in 67 children found Ringer’s lactate shortened time to DKA resolution versus 0.9% saline, with less hyperchloraemia. PICO summary and expert commentary.
A phase I/II randomized trial found long-term controlled-release oral GABA (Remygen) did not improve C-peptide, CGM metrics, or HbA1c in men with long-standing type 1 diabetes, and side effects were common. PICO summary and expert commentary.
A single-arm extension found HbA1c was sustained over 30 weeks in adults with type 1 diabetes who switched to inhaled technosphere insulin plus degludec. PICO summary and expert commentary.
A 13-week single-arm switch study tested inhaled technosphere insulin plus degludec against participants’ own baseline in 49 adults with type 1 diabetes. PICO summary and expert commentary.